Gilead submits NDA to FDA for Viread

FOSTER CITY, Calif. Gilead Sciences has submitted a new drug application to the Food and Drug Administration for its drug Viread, for the treatment of chronic hepatitis B in adults.

The drug is already approved in the U.S. for the treatment of HIV as part of a combination antiretroviral therapy.  The company is asking for the new application after successful data from two Phase III trials that were compared with the company’s hepatitis medication Hepsera.

Login or Register to post a comment.